Publicaciones (24) Publicaciones de DAVID BÜCHSER GARCÍA

2024

  1. Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?

    Clinical Genitourinary Cancer, Vol. 22, Núm. 1, pp. 56-66

  2. Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities

    Clinical and Translational Radiation Oncology, Vol. 45

  3. Prospective study of HDR brachytherapy (BT), external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT): 10-years experience of an MRI-guided approach

    Radiotherapy and Oncology, Vol. 190

2022

  1. Bone health and therapeutic agents in advanced prostate cancer

    Frontiers in Bioscience - Landmark, Vol. 27, Núm. 1

  2. MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial

    British Journal of Radiology, Vol. 95, Núm. 1131, pp. 1-7

2021

  1. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: Toxicity, prostatespecific antigen kinetics, and cancer control

    Journal of Contemporary Brachytherapy, Vol. 13, Núm. 1, pp. 12-17

  2. Salvage local treatment for localized radio-recurrent prostate cancer: A narrative review and future perspectives

    Future Oncology, Vol. 17, Núm. 31, pp. 4207-4219

2020

  1. MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?

    Clinical and Translational Radiation Oncology, Vol. 24, pp. 135-139

  2. Oligometastatic prostate adenocarcinoma. Clinical-pathologic study of a histologically under-recognized prostate cancer

    Journal of Personalized Medicine, Vol. 10, Núm. 4, pp. 1-9

  3. Pain response and quality of life assessment in patients with moderate/severe neuropathic pain due to bone metastasis undergoing treatment with palliative radiotherapy and tapentadol: A prospective multicentre pilot study

    Journal of Medical Imaging and Radiation Oncology, Vol. 64, Núm. 6, pp. 859-865

  4. Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial

    Radiotherapy and Oncology, Vol. 146, pp. 16-20

2019

  1. Impact of rectum and bladder anatomy in intrafractional prostate motion during hypofractionated radiation therapy

    Clinical and Translational Oncology, Vol. 21, Núm. 5, pp. 607-614

  2. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study

    Radiotherapy and Oncology, Vol. 135, pp. 13-18

  3. Long-term Outcomes and Patterns of Failure Following Trimodality Treatment With Bladder Preservation for Invasive Bladder Cancer

    Urology, Vol. 124, pp. 183-190

  4. author reply

    Urology

2018

  1. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial

    Radiotherapy and Oncology, Vol. 126, Núm. 2, pp. 278-282

  2. Pretreatment Multiparametric Magnetic Resonance Imaging Findings Are More Accurate Independent Predictors of Outcome Than Clinical Variables in Localized Prostate Cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 101, Núm. 5, pp. 1172-1178

2017

  1. Products based on olive oil, betaine, and xylitol in the post-radiotherapy xerostomia

    Reports of Practical Oncology and Radiotherapy, Vol. 22, Núm. 1, pp. 71-76

  2. Protocolo de tratamiento paliativo radioterápico en enfermedades oncológicas. Indicaciones. Pautas terapéuticas

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 12, Núm. 34, pp. 2065-2069

  3. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer

    Clinical and Translational Oncology, Vol. 19, Núm. 9, pp. 1161-1167